Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.
CAS Registry Number
1146887-67-3
Molecular formula
Not available
Molecular weight
Not available
Drug class
Antisense oligonucleotideinvestigational inhibitor of insulin receptor substrate-1 (IRS-1) expression
Mechanism of action
A synthetic antisense oligonucleotide designed to hybridise to IRS-1 mRNA, reducing expression of insulin receptor substrate-1 and downstream pro-angiogenic signalling involved in pathological corneal neovascularisation.
Indications / reported uses
Investigational topical ophthalmic treatment studied for corneal neovascularisation, including neovascularisation associated with herpetic keratitis and high-risk corneal transplantation. Aganirsen remains investigational; it should not be presented as an approved routine therapy.
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
ERA assessment scope
Project-specific environmental risk assessment support
The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.
Phase I exposure screening and trigger evaluation.
Environmental fate and ecotoxicity review, with Phase II work where required.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope
Environmental Risk Assessment (ERA)
ReguSight provides project-specific support for the Aganirsen Environmental Risk Assessment (ERA) (the Aganirsen ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.
Assessment may cover
Product, active-substance identity, formulation, route and intended-market review.
Phase I environmental exposure screening and applicable trigger evaluation.
Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
Data-gap analysis, study strategy, assumptions and scientific reporting.
The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.